Literature DB >> 26386811

Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment.

Steven M Holland1, Donna L Bratton2, Ruby F Fernandez-Boyanapalli2, Emilia Liana Falcone1, Christa S Zerbe1, Beatriz E Marciano1, S Courtney Frasch2, Peter M Henson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26386811      PMCID： PMC4640967          DOI： 10.1016/j.jaci.2015.07.034

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  10 in total

Review 1.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

Review 2.  The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology.

Authors:  Mate Kiss; Zsolt Czimmerer; Laszlo Nagy
Journal:  J Allergy Clin Immunol       Date:  2013-08       Impact factor: 10.793

Review 3.  Macrophages, inflammation, and insulin resistance.

Authors:  Jerrold M Olefsky; Christopher K Glass
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

4.  Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD).

Authors:  Joanne R Brown; David Goldblatt; Joanna Buddle; Louise Morton; Adrian J Thrasher
Journal:  J Leukoc Biol       Date:  2003-05       Impact factor: 4.962

5.  PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease.

Authors:  Ruby Fernandez-Boyanapalli; S Courtney Frasch; David W H Riches; R William Vandivier; Peter M Henson; Donna L Bratton
Journal:  Blood       Date:  2010-08-06       Impact factor: 22.113

6.  Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease.

Authors:  Ruby F Fernandez-Boyanapalli; S Courtney Frasch; Stacey M Thomas; Kenneth C Malcolm; Michael Nicks; Ronald J Harbeck; Claudia V Jakubzick; Raphael Nemenoff; Peter M Henson; Steven M Holland; Donna L Bratton
Journal:  J Allergy Clin Immunol       Date:  2014-12-10       Impact factor: 10.793

7.  An efferocytosis-induced, IL-4-dependent macrophage-iNKT cell circuit suppresses sterile inflammation and is defective in murine CGD.

Authors:  Melody Yue Zeng; Duy Pham; Juhi Bagaitkar; Jianyun Liu; Karel Otero; Ming Shan; Thomas A Wynn; Frank Brombacher; Randy R Brutkiewicz; Mark H Kaplan; Mary C Dinauer
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

8.  ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease.

Authors:  Kelly L Brown; Johan Bylund; Kelly L MacDonald; George X Song-Zhao; Melissa R Elliott; Reza Falsafi; Robert E W Hancock; David P Speert
Journal:  Clin Immunol       Date:  2008-07-26       Impact factor: 3.969

9.  Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease.

Authors:  Duangmanee Sanmun; Erika Witasp; Siriporn Jitkaew; Yulia Y Tyurina; Valerian E Kagan; Anders Ahlin; Jan Palmblad; Bengt Fadeel
Journal:  Am J Physiol Cell Physiol       Date:  2009-07-01       Impact factor: 4.249

10.  PPARγ in Inflammatory Bowel Disease.

Authors:  Vito Annese; Francesca Rogai; Alessia Settesoldi; Siro Bagnoli
Journal:  PPAR Res       Date:  2012-09-10       Impact factor: 4.964
  10 in total
  17 in total

1.  Impaired efferocytosis by monocytes in multiple myeloma.

Authors:  Ying Yu Liang; Ilse Schwarzinger; Ingrid Simonitsch-Klupp; Hermine Agis; Rudolf Oehler
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

Review 2.  Clearance of apoptotic neutrophils and resolution of inflammation.

Authors:  Mallary C Greenlee-Wacker
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

Review 3.  Advances in clinical immunology in 2015.

Authors:  Javier Chinen; Luigi D Notarangelo; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2016-12       Impact factor: 10.793

4.  Antioxidants and Chronic Obstructive Pulmonary Disease.

Authors:  Félix-Antoine Vézina; André M Cantin
Journal:  Chronic Obstr Pulm Dis       Date:  2018-10-08

5.  PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice.

Authors:  Tobias Gutting; Christian A Weber; Philip Weidner; Frank Herweck; Sarah Henn; Teresa Friedrich; Shuiping Yin; Julia Kzhyshkowska; Timo Gaiser; Klaus-Peter Janssen; Wolfgang Reindl; Matthias P A Ebert; Elke Burgermeister
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

6.  Oxidants in Physiological Processes.

Authors:  Ulla G Knaus
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.

Authors:  Elizabeth M Kang
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

Review 8.  PPARγ in Bacterial Infections: A Friend or Foe?

Authors:  Aravind T Reddy; Sowmya P Lakshmi; Raju C Reddy
Journal:  PPAR Res       Date:  2016-09-28       Impact factor: 4.964

Review 9.  The immune response to secondary necrotic cells.

Authors:  Monika Sachet; Ying Yu Liang; Rudolf Oehler
Journal:  Apoptosis       Date:  2017-10       Impact factor: 4.677

Review 10.  Raising the 'Good' Oxidants for Immune Protection.

Authors:  Alexia Dumas; Ulla G Knaus
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.